Alnylam Pharmaceuticals (ALNY) Tax Provisions (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly Tax Provisions of $15.7 million for Q1 2026, down 1.39% year-on-year from $15.9 million in Q1 2025, and up 161.95% on a QoQ basis from -$25.3 million in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 12 years of Tax Provisions data on file, last reported at $15.7 million in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions fell 1.39% year-over-year to $15.7 million; the trailing twelve-month figure through Mar 2026 stood at $9.2 million (up 110.72% YoY), and the FY2025 full-year result was $9.4 million, up 109.48% from the prior year.
- Tax Provisions for Q1 2026 stood at $15.7 million, up from -$25.3 million in the prior quarter.
- Across five years, Tax Provisions topped out at $30.9 million in Q2 2025 and bottomed at -$110.2 million in Q4 2024.
- The 5-year median for Tax Provisions is $1.8 million (2023), against an average of -$3.7 million.
- The widest annual swing landed in 2023, when Tax Provisions soared 13091.3%; it then sank 60315.85% in 2024.
- A 5-year view of Tax Provisions shows it stood at $472000.0 in 2022, then sank by 61.23% to $183000.0 in 2023, then tumbled by 60315.85% to -$110.2 million in 2024, then surged by 77.06% to -$25.3 million in 2025, then jumped by 161.95% to $15.7 million in 2026.
- The last three Tax Provisions figures came in at $15.7 million (Q1 2026), -$25.3 million (Q4 2025), and -$12.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.66 Mn |
| Dec 31, 2025 | -25.28 Mn |
| Sep 30, 2025 | -12.12 Mn |
| Jun 30, 2025 | 30.92 Mn |
| Mar 31, 2025 | 15.88 Mn |
| Dec 31, 2024 | -110.20 Mn |
| Sep 30, 2024 | 2.91 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Mar 31, 2024 | 2.35 Mn |
| Dec 31, 2023 | 183,000.00 |
| Sep 30, 2023 | 2.99 Mn |
| Jun 30, 2023 | 1.82 Mn |
| Mar 31, 2023 | 1.74 Mn |
| Dec 31, 2022 | 472,000.00 |
| Sep 30, 2022 | -23,000.00 |
| Jun 30, 2022 | 2.73 Mn |
| Mar 31, 2022 | 985,000.00 |
| Dec 31, 2021 | -1.84 Mn |
| Sep 30, 2021 | 278,000.00 |
| Jun 30, 2021 | 1.23 Mn |
| Mar 31, 2021 | 1.02 Mn |
| Dec 31, 2020 | -59,000.00 |
| Sep 30, 2020 | 839,000.00 |
| Jun 30, 2020 | 1.33 Mn |
| Mar 31, 2020 | 575,000.00 |
| Dec 31, 2019 | -398,000.00 |
| Sep 30, 2019 | -394,000.00 |
| Jun 30, 2019 | 960,000.00 |
| Mar 31, 2019 | 695,000.00 |
| Dec 31, 2018 | 361,000.00 |
| Sep 30, 2018 | 445,000.00 |
| Jun 30, 2018 | 79,000.00 |
| Mar 31, 2018 | -62,000.00 |
| Dec 31, 2013 | 3.02 Mn |
| Sep 30, 2013 | -2.27 Mn |
| Jun 30, 2013 | -2.88 Mn |
| Mar 31, 2013 | -562,000.00 |
| Dec 31, 2010 | 427,000.00 |
| Sep 30, 2010 | 298,000.00 |
| Jun 30, 2010 | -229,000.00 |
| Mar 31, 2010 | 18,000.00 |
| Dec 31, 2009 | -439,000.00 |
| Sep 30, 2009 | -552,000.00 |
| Jun 30, 2009 | 908,000.00 |